Bli medlem
Bli medlem

Du är här

2016-03-14

Targovax ASA: Targovax to present at forthcoming Life Science and Investor conferences

Oslo 14 March 2016 - Targovax, a clinical stage immuno-oncology company
developing targeted immunotherapy treatments for cancer patients, announces
that members of its senior management team will participate in the following
life sciences and investor conferences:

INVESTOR/PARTNERING CONFERENCES

Sachs Associates 9thAnnual ELSCEO Forum&Exhibition
Zurich, 15 March, 2016
Participants: Gunnar Gårdemyr (CEO), Øystein Soug (CFO) and Magnus Jäderberg
(CMO)
Presentation time: 10:45
Venue: Hilton Zurich Airport Hotel

BIO-EUROPE Spring 2016

Stockholm, 5-6 April, 2016
Participants: Gunnar Gårdemyr (CEO) and Peter Skorpil (VP Business
Development)

BioEquity

Copenhagen, 10-11 May, 2016
Participants: Gunnar Gårdemyr (CEO), Øystein Soug (CFO) and Magnus Jäderberg
(CMO)

BIO International Convention

San Francisco, 6-9 June, 2016
Participants: Gunnar Gårdemyr (CEO) and Peter Skorpil (VP Business
Development)

SCIENTIFIC CONFERENCES

Royal Swedish Academy of Engineering Sciences

Stockholm, 16 May, 2016
Participants: Magnus Jäderberg (CMO)

ASCO

Chicago, 3-7 June, 2016
Participants: Magnus Jäderberg (CMO)

The Presentations will be available to download atwww.targovax.comfollowing
the event.

For further information, please contact:

Gunnar Gårdemyr
CEO
Phone: +41 798 340 585
Email:ggardemyr@targovax.com

Øystein Soug
CFO
Phone: +47 906 56 525
Email:oystein.soug@targovax.com

About Targovax
:"Arming the patient's immune system to fight cancer"

Targovax is a clinical stage immuno-oncology company developing targeted
immunotherapy treatments for cancer patients. Targovax has a broad and
diversified immune therapy portfolio and aim to become a leader in its area.
The company is currently developing two complementary and highly targeted
approaches in immuno-oncology:

ONCOS - 102
is a virus-based immunotherapy platform based on engineered oncolytic viruses
armed with potent immune-stimulating transgenes targeting solid tumors. This
treatment may reinstate the immune system's capacity to recognize and attack
cancer cells.

TG01 and TG02
are part of a peptide-based immunotherapy platform targeting the difficult to
treat RAS mutations found in more than 85% of pancreatic cancers, 50% of
colorectal cancer and 20-30% of all cancers. Targovax works towards
demonstrating that TG vaccines will prolong time to cancer progression and
increase survival.

The product candidates will be developed in combination with multiple
treatments in several cancer indications, including checkpoint inhibitors.
Targovax also has a number of other cancer immune therapy candidates in the
early stage of development. For more information go towww.targovax.com.

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Targovax ASA via Globenewswire

HUG#1994178

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.